This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
Reata Surges on $350 Million Investment Deal With Blackstone
by Zacks Equity Research
Reata (RETA) announces a royalty and equity investment deal with Blackstone Group, which will support development of its lead pipeline candidate, bardoxolone methyl, in chronic kidney diseases.
The Zacks Analyst Blog Highlights: AbbVie, Eagle Bancorp Montana, H&R Block, Mackinac Financial and Virtu Financial
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AbbVie, Eagle Bancorp Montana, H&R Block, Mackinac Financial and Virtu Financial
5 Defensive Stocks to Buy as Coronavirus Cases Rise Again
by Zacks Equity Research
An alarming rise in the number of coronavirus cases results in volatility in the market and raises the appeal of defensive stocks
Pharma Stock Roundup: Coronavirus Updates From ABBV, LLY, JNJ, FDA Approvals
by Kinjel Shah
J&J (JNJ), AbbVie (ABBV) and Lilly (LLY) make progress in coronavirus research efforts.
Go Defensive to Beat Market Turbulence With These 4 Stocks
by Zacks Equity Research
Opting for a defensive strategy in the current market scenario could be ideal, given that the Dow just booked its worst daily drop in more than two-and-a-half-months.
6 Defensive Stocks to Beat the Volatility
by Sejuti Banerjea
Low-beta dividend paying names may be the best way to go in a volatile market.
AbbVie Inks Deal With Genmab, Announces ADC Candidate Data
by Zacks Equity Research
AbbVie (ABBV) signs deal with Genmab to jointly develop three early-stage bispecific antibody product candidates. Its novel ADC candidate, ABBV-3373 demonstrates clinical activity in study.
AbbVie (ABBV) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
AbbVie (ABBV) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Top Ranked Value Stocks to Buy for June 11th
by Zacks Equity Research
Here are three stocks with buy rank and strong value characteristics for investors to consider today, June 11th
Vertex's Kalydeco Wins Approval in EU for CF in Children
by Zacks Equity Research
Vertex's (VRTX) Kalydeco gains EU nod for use in cystic fibrosis patients aged from six months to 18 years with the R117H mutation in the CFTR gene.
Why AbbVie (ABBV) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
ESG Investing Trend to Stay Strong Post Pandemic: 5 Top Picks
by Zacks Equity Research
Investing in ESG stocks bear lesser financial risks due to their focus on environment, employees and supply chain. They proved resilient during the coronavirus pandemic and will continue to surge.
AbbVie (ABBV) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $94.59, marking a +0.79% move from the previous day.
Merck's Antibiotic Recarbrio Gets FDA Nod for New Indication
by Zacks Equity Research
The FDA approves Merck's (MRK) sNDA seeking approval for its antibacterial injection Recarbrio regarding a new indication. The application was filed in February 2020.
AbbVie (ABBV) Joins Race for Developing Coronavirus Treatment
by Zacks Equity Research
AbbVie (ABBV) collaborates with three parties for developing an antibody-based treatment for COVID-19.
3 Top Dividend Stocks to Maximize Your Retirement Income - June 08, 2020
by Zacks Equity Research
The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.
Powerful Proof Anyone Can Invest for an Early Retirement - June 08, 2020
by Zacks Equity Research
Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.
Silgan, Canada Goose, Sempra Energy, Fortinet and Abbvie highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Silgan, Canada Goose, Sempra Energy, Fortinet and Abbvie highlighted as Zacks Bull and Bear of the Day
4 Reasons Why Wall Street's V-Shaped Recovery Should Continue
by Nalak Das
Reopening of the economy and recently released better-than expected economic data strengthened investors' confidence in U.S. stocks.
The Market Timing Secrets No One Talks About - June 05, 2020
by Zacks Equity Research
In the long-run, does consistent market timing really matter to be a successful investor?
The Zacks Analyst Blog Highlights: AbbVie, Amkor Technology, Calix, The Hain Celestial Group and Acacia Communications
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AbbVie, Amkor Technology, Calix, The Hain Celestial Group and Acacia Communications
Pharma Stock Roundup: LLY Coronavirus Antibody Phase I Study Initiation, FDA Approvals
by Kinjel Shah
Lilly (LLY) begins phase I study on a potential COVID-19 antibody therapy. FDA grants label expansion approvals to several drugs.
A "Don't Fight the Fed" Rally: Zacks June Strategy
by John Blank
In early May, international travel shutdowns remained the norm. Some U.S. state governors gingerly lifted their "Stay-at-Home" decrees. In early June, a number of European travel shutdowns are ending, and all 50 U.S. states are open for business.
Is AbbVie (ABBV) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (ABBV) Outperforming Other Medical Stocks This Year?
Novartis (NVS) Announces Positive Data From Cosentyx Study
by Zacks Equity Research
Novartis (NVS) reports encouraging data from the phase III PREVENT study evaluating Cosentyx in patients with non-radiographic axial spondyloarthritis.